News
-
iBio Announces Successful Completion Of H1N1 Influenza Vaccine Phase 1 Clinical Trial
3/22/2012
iBio, Inc. (NYSE AMEX: IBIO) today announced completion of the first human trial of iBioLaunch-produced H1N1 influenza vaccine (HAC1) that began September 13, 2010. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of HAC1 produced by iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology.
-
Nano-Sized Protein Clusters Address Major Challenge Of Drug Delivery
2/21/2012
A new form of proteins discovered by researchers at The University of Texas at Austin could drastically improve treatments for cancer and other diseases, as well as overcome some of the largest challenges in therapeutics: delivering drugs to patients safely, easily and more effectively.
-
Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors
1/10/2012
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
-
HIV Study Named 2011 Breakthrough Of The Year By Science
12/28/2011
The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year.
-
KPS Selected As Functional Service Provider On GlobeImmune Clinical Trials
11/8/2011
Kellman Pharmaceutical Services (KPS), an international full-service Contract Research Organization (CRO), is now working with GlobeImmune as a Functional Service Provider (FSP) for monitoring services.
-
Cempra Announces Comparable Efficacy Of Oral Solithromycin (CEM-101) Compared With Levofloxacin In Phase II Clinical Trial In Patients With Community-Acquired Bacterial Pneumonia (CABP)
9/20/2011
Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).
-
AVI BioPharma Expands Clinical Pipeline With Initiation Of Phase 1 Study Of Influenza Therapeutic Candidate
6/22/2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it initiated dosing of volunteers in a Phase 1 clinical study of AVI-7100, the Company's lead drug candidate for the treatment of influenza.
This website uses cookies to ensure you get the best experience on our website. Learn more